Herein research deals with one of the most important problem of pediatry, namely, the development of treatment and aftercare measures for children with such diseases as bronchial asthma, atopic eczema, and allergic rhinitis by way of vitamin-D3 administration. In the herein research there was investigated vitamin D-status in children with allergic diseases and healthy ones; 25-hydroxyvitamin D level in blood serum investigated in children with different severities of allergic disease, in different forms of the disease; in different periods of the disease, in different seasons of the year; by vitamin D3 medication in dose of 2000 IU every day in 2-month course, in heighten doses of 4000-5000 IU every day during 2 months. It were studied the peculiarities of the allergic disease clinical course by vitamin D administrating; it was detected basal value of A-, G-, M-, E-immunoglobulin and cytokines of allergic inflammation - Interleukin-4 (IL-4) and Interleukin-10 (IL-10) in patients, and dynamics of A-, G-, M-immunoglobulin, also IL-4 and IL-10 by way of entry of vitamin D with endogenous and exogenous (medication taking) sources of entry. It has been found the correlation between disease severity and 25-hydroxyvitamin D level in blood serum; what harder were the manifestations that lower was 25-hydroxyvitamin D level in blood serum. It is established authentic decrease of Interleukin-4 (IL-4) in blood of children during exacerbation period of disease (p<0.05), however authentically lower index of IL-4 was observed after 4000-5000 IU of cholecalciferol administration than after summer period; and after vitamin D3 medication taking in dose of 2000 IU (Z=2.934; p<0,05 and Z=2.803; p<0.05 accordingly). It was being observed a tendency to IL-4 decreasing in blood of children in remission of allergic disease. It was also being noticed authentic decrease of IL-10 in children with allergic diseases during exacerbation and remission (p<0.05), on the back of vitamin D3 entry in human body of patients, at this, the lowest indexes of IL-10 were established after cholecalciferol administration in heightened doses of (4000-5000 IU). The received findings showed that vitamin D took part in allergic inflammation processes, perhaps, by inhibiting it during exacerbation and remission periods of allergic disease. Looking at this, it is supposed sensibly that cholecalciferol to be administered during remission and exacerbation periods, and probably, the dose of vitamin D3 to be heightened during exacerbation period. Positive dynamics of immunologic indexes on the back of vitamin D entry in human body of children usually coincides with therapeutic effect by vitamin D3 administrating in heightened doses of (4000-5000) IU that is confirmed clinically. In the course of our research, by comparing individually the dynamics of 25-hydroxyvitamin D level in every child and dynamics of IL-4, IL-10 on the back of cholecalciferol entry in human body with endogenous and exogenous sources of entry during different periods of disease, it is cleared up, that by heightening of 25-hydroxyvitamin D level in blood serum, IL-4 and IL-10 decreased, it is established intense correlating feedback connection between such indexes as what prove that vitamin D participates in processes of allergic inflammation decrease in children diagnosed with.
